ATE359069T1 - Therapeutische zusammenstellungen - Google Patents
Therapeutische zusammenstellungenInfo
- Publication number
- ATE359069T1 ATE359069T1 AT99946906T AT99946906T ATE359069T1 AT E359069 T1 ATE359069 T1 AT E359069T1 AT 99946906 T AT99946906 T AT 99946906T AT 99946906 T AT99946906 T AT 99946906T AT E359069 T1 ATE359069 T1 AT E359069T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- physiologically acceptable
- therapeutic compositions
- acceptable ketosis
- ketosis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000007976 Ketosis Diseases 0.000 abstract 2
- 230000004140 ketosis Effects 0.000 abstract 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 abstract 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10037198P | 1998-09-15 | 1998-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359069T1 true ATE359069T1 (de) | 2007-05-15 |
Family
ID=22279402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99946906T ATE359069T1 (de) | 1998-09-15 | 1999-09-15 | Therapeutische zusammenstellungen |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20010014696A1 (de) |
| EP (1) | EP1123094B1 (de) |
| JP (1) | JP2002524506A (de) |
| KR (1) | KR100805490B1 (de) |
| CN (1) | CN1273129C (de) |
| AT (1) | ATE359069T1 (de) |
| AU (1) | AU767238B2 (de) |
| BR (1) | BR9913680A (de) |
| CA (1) | CA2339941A1 (de) |
| DE (1) | DE69935799T2 (de) |
| DK (1) | DK1123094T3 (de) |
| ES (1) | ES2283133T3 (de) |
| NZ (1) | NZ509739A (de) |
| PT (1) | PT1123094E (de) |
| RU (1) | RU2242227C2 (de) |
| WO (1) | WO2000015216A1 (de) |
| ZA (1) | ZA200101260B (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124589B2 (en) | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US20020006959A1 (en) * | 2000-05-01 | 2002-01-17 | Henderson Samuel T. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism |
| EP1648952B1 (de) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nahrungszusätze und therapeutische zusammensetzungen, die (r)-3-hydroxybutyratderivate enthalten |
| WO2005021013A1 (ja) * | 2003-09-01 | 2005-03-10 | Earthus, Inc. | β−ヒドロキシ短〜中鎖脂肪酸重合体 |
| US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
| GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| WO2006020179A2 (en) | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
| US20070281892A1 (en) * | 2004-09-21 | 2007-12-06 | Martin Keith F | Dopaminergic Mimetics |
| GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
| EP1915144A4 (de) | 2005-06-20 | 2009-08-19 | Accera Inc | Verfahren zur reduzierung von oxidativen schäden und zur verbesserung der mitochondrien-effizienz |
| RU2317304C1 (ru) * | 2006-04-17 | 2008-02-20 | Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (СО РАН) | Пептид, обладающий апоптотической активностью по отношению к раковым клеткам человека |
| US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US20080089981A1 (en) * | 2006-10-17 | 2008-04-17 | N.V. Nutricia | Ketogenic diet |
| WO2008120778A1 (ja) | 2007-03-30 | 2008-10-09 | Earthus, Inc. | ケトン体生成促進剤組成物 |
| BRPI0811052A2 (pt) * | 2007-04-12 | 2015-01-27 | Univ Minnesota | Composições de proteção de isquemia/reperfusão e métodos de uso. |
| CN101293831B (zh) * | 2007-04-27 | 2013-09-18 | 汕头大学 | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 |
| KR101335021B1 (ko) | 2007-07-31 | 2013-12-12 | 액세라인크 | 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물 |
| CA2702577A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
| DK2240017T3 (da) | 2008-01-04 | 2019-06-17 | Univ Oxford Innovation Ltd | Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler |
| US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| WO2010084356A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| CN102753186B (zh) * | 2010-01-08 | 2016-09-14 | Isis制药公司 | 血管生成素样3表达的调节 |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| AU2011281336B2 (en) | 2010-07-20 | 2015-03-05 | Junaxo, Inc. | Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders |
| EP2914251B1 (de) | 2012-11-05 | 2019-08-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ketonkörper zum schutz von geweben vor beschädigung durch ionisierende strahlung |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| SG11201507685UA (en) | 2013-03-14 | 2015-10-29 | Isis Innovation | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
| KR102499654B1 (ko) | 2013-03-19 | 2023-02-13 | 유니버시티 오브 사우스 플로리다 | 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법 |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| EP3558280B1 (de) | 2016-12-21 | 2023-06-07 | Universitäts-kinderspital Beider Basel | Migränevorbeugung und -behandlung |
| MX390420B (es) * | 2016-12-23 | 2025-03-20 | Univ Leuven Kath | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos. |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900022854A1 (it) * | 2019-12-03 | 2021-06-03 | Dr Schaer S P A | Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica |
| WO2021195477A1 (en) | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| KR20240037239A (ko) | 2021-07-17 | 2024-03-21 | 케토스위스 아게 | 케톤체 또는 케톤 생성 화합물과 진통제 또는 항산화제의 조합 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5286842A (en) * | 1991-07-01 | 1994-02-15 | Mitsubishi Kasei Corporation | Process for producing a biodegradable polymer |
| RU2064793C1 (ru) * | 1992-03-31 | 1996-08-10 | Игорь Васильевич Комиссаров | Стресспротективное средство, обладающее антиамнестическим, антигипоксическим, противотревожным и противошоковым действием |
| JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
| JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| CA2283642C (en) * | 1997-03-17 | 2012-05-15 | Btg International Limited | Therapeutic compositions |
| AU748733B2 (en) * | 1998-01-07 | 2002-06-13 | Metabolix, Inc. | Animal nutrition compositions |
| US6380244B2 (en) * | 1998-07-22 | 2002-04-30 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
-
1999
- 1999-09-15 WO PCT/US1999/021015 patent/WO2000015216A1/en not_active Ceased
- 1999-09-15 RU RU2001110097/15A patent/RU2242227C2/ru not_active IP Right Cessation
- 1999-09-15 KR KR1020017003343A patent/KR100805490B1/ko not_active Expired - Fee Related
- 1999-09-15 EP EP99946906A patent/EP1123094B1/de not_active Expired - Lifetime
- 1999-09-15 JP JP2000569800A patent/JP2002524506A/ja active Pending
- 1999-09-15 CN CNB998108375A patent/CN1273129C/zh not_active Expired - Fee Related
- 1999-09-15 CA CA002339941A patent/CA2339941A1/en not_active Abandoned
- 1999-09-15 DK DK99946906T patent/DK1123094T3/da active
- 1999-09-15 ES ES99946906T patent/ES2283133T3/es not_active Expired - Lifetime
- 1999-09-15 PT PT99946906T patent/PT1123094E/pt unknown
- 1999-09-15 NZ NZ509739A patent/NZ509739A/en not_active IP Right Cessation
- 1999-09-15 BR BR9913680-5A patent/BR9913680A/pt not_active Application Discontinuation
- 1999-09-15 AT AT99946906T patent/ATE359069T1/de active
- 1999-09-15 AU AU59212/99A patent/AU767238B2/en not_active Ceased
- 1999-09-15 DE DE69935799T patent/DE69935799T2/de not_active Expired - Lifetime
-
2001
- 2001-02-14 ZA ZA200101260A patent/ZA200101260B/en unknown
- 2001-03-06 US US09/799,124 patent/US20010014696A1/en not_active Abandoned
-
2003
- 2003-12-15 US US10/734,586 patent/US7351736B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK1123094T3 (da) | 2007-08-20 |
| AU5921299A (en) | 2000-04-03 |
| ES2283133T3 (es) | 2007-10-16 |
| WO2000015216A1 (en) | 2000-03-23 |
| EP1123094B1 (de) | 2007-04-11 |
| DE69935799T2 (de) | 2007-12-27 |
| US20040171671A1 (en) | 2004-09-02 |
| KR100805490B1 (ko) | 2008-02-20 |
| RU2242227C2 (ru) | 2004-12-20 |
| DE69935799D1 (de) | 2007-05-24 |
| AU767238B2 (en) | 2003-11-06 |
| HK1035665A1 (en) | 2001-12-07 |
| ZA200101260B (en) | 2001-08-16 |
| CN1273129C (zh) | 2006-09-06 |
| PT1123094E (pt) | 2007-06-28 |
| EP1123094A1 (de) | 2001-08-16 |
| US20010014696A1 (en) | 2001-08-16 |
| JP2002524506A (ja) | 2002-08-06 |
| CA2339941A1 (en) | 2000-03-23 |
| BR9913680A (pt) | 2001-06-05 |
| EP1123094A4 (de) | 2001-10-04 |
| NZ509739A (en) | 2003-10-31 |
| US7351736B2 (en) | 2008-04-01 |
| KR20010079830A (ko) | 2001-08-22 |
| CN1316902A (zh) | 2001-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69935799D1 (de) | Therapeutische zusammenstellungen | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| MX9203543A (es) | Medicamento. | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| NL300382I1 (nl) | Treatment of pompe's disease | |
| CA2223403A1 (en) | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds | |
| MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
| CA2197210A1 (en) | Intravenous alendronate formulations | |
| WO2001036510A3 (en) | Use of poly(diallylamine) polymers | |
| SE8704248D0 (sv) | Medical use | |
| DE3879873D1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| KR900015718A (ko) | 골관절염 치료제 | |
| MXPA02003495A (es) | Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos. | |
| SE8500996D0 (sv) | Method of treatment | |
| EE9700231A (et) | Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks | |
| Rail et al. | Improvement in nerve condition after plasma exchange for Guillain-Barré syndrome | |
| DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| ATE207353T1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
| Káldor et al. | Enhancement of methyldopa metabolism with barbiturate | |
| SU944583A1 (ru) | Способ реабилитации травматических поражений мышц | |
| UA10301A (uk) | Спосіб лікуваhhя раку шлуhку | |
| DK601788D0 (da) | Anvendelse af antibiotikaene ll-e19020alfa og ll-e19020beta til behandling af visse fjerkraesygdomme | |
| UA30251A (uk) | Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи | |
| UA15281A (uk) | Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця | |
| RU2000106699A (ru) | Способ лечения заболеваний методом настройки биоритмов организма |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1123094 Country of ref document: EP |